A Finnish founder mutation in <i>RAD51D</i>: analysis in breast, ovarian, prostate, and colorectal cancer: Table 1

The results of this study on familial and unselected breast, ovarian, colorectal, and prostate cancer patients suggest that RAD51D is primarily a moderate penetrance susceptibility gene for ovarian cancer, with clinical significance for the carriers.